{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:14:17Z","timestamp":1788491657393,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.013","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:50Z","timestamp":1749770150000},"page":"362-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiation Therapy in Node-Positive Prostate Cancer: Current Evidence and Future Directions"],"prefix":"10.1016","volume":"35","author":[{"given":"Michael","family":"Melton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Angrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9883","authenticated-orcid":false,"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0001","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0002","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.prro.2012.11.011","article-title":"Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival","volume":"3","author":"Tward","year":"2013","journal-title":"Pract Radiat Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.013_bib0003","doi-asserted-by":"crossref","first-page":"djv119","DOI":"10.1093\/jnci\/djv119","article-title":"Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer","volume":"107","author":"Lin","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.08.018","article-title":"The prognosis and the impact of radiotherapy in clinically regional lymph node-positive prostate cancer: Which patients are candidates for local therapy with radiation?","volume":"38","author":"Ieiri","year":"2020","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"Chow","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0006","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.eururo.2020.06.017","article-title":"Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study","volume":"78","author":"Ploussard","year":"2020","journal-title":"Eur Urol"},{"issue":"10231","key":"10.1016\/j.semradonc.2025.04.013_bib0007","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0008","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"NCCN Guidelines(R) Insights: Prostate Cancer, Version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0009","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.013_bib0010","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.21873\/invivo.13341","article-title":"Predictors of Outcomes in Patients With Clinically Lymph Node Positive Prostate Cancer After Definitive Radiotherapy","volume":"37","author":"Kim","year":"2023","journal-title":"In Vivo"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0011","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.2005.08.141","article-title":"Androgen suppression plus radiation versus radiation alone for patients with stage D1\/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31","volume":"23","author":"Lawton","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10162","key":"10.1016\/j.semradonc.2025.04.013_bib0012","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0013","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3857\/roj.2024.00080","article-title":"Hypofractionated radiation therapy combined with androgen deprivation therapy for clinically node-positive prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"Radiat Oncol J"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.013_bib0014","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0015","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ijrobp.2009.11.044","article-title":"Predictors of androgen deprivation therapy efficacy combined with prostatic irradiation: the central role of tumor stage and radiation dose","volume":"79","author":"Williams","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0016","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.013_bib0018","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"10323","key":"10.1016\/j.semradonc.2025.04.013_bib0019","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.013_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS156","article-title":"Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer (ENZARAD)","volume":"36","author":"Williams","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0021","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00120-017-0329-0","volume":"56","author":"Rexer","year":"2017","journal-title":"Urologe A"},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.013_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS396","article-title":"DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer","volume":"41","author":"Niazi","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.04.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5127","article-title":"ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases","volume":"42","author":"Oudard","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"9809","key":"10.1016\/j.semradonc.2025.04.013_bib0024","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0025","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jamaoncol.2015.4350","article-title":"Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial","volume":"2","author":"James","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0026","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2023.07.020","article-title":"Consensus Delineation Guidelines for Pelvic Lymph Node Radiation Therapy of Prostate Cancer: On Behalf of the Francophone Group of Urological Radiation Therapy (GFRU)","volume":"118","author":"De Hertogh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0027","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2016.07.043","article-title":"Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage","volume":"71","author":"Spratt","year":"2017","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.semradonc.2025.04.013_bib0028","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1002\/cam4.2985","article-title":"Clinical outcomes of definitive whole pelvic radiotherapy for clinical lymph node metastatic prostate cancer","volume":"9","author":"Tsuchida","year":"2020","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0029","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11547-021-01435-8","article-title":"Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting","volume":"127","author":"Francolini","year":"2022","journal-title":"Radiol Med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0030","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00066-023-02129-y","article-title":"Whole-pelvic irradiation with boost to involved nodes and prostate in node-positive prostate cancer-long-term data from the prospective PLATIN-2 trial","volume":"200","author":"Fink","year":"2024","journal-title":"Strahlenther Onkol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.013_bib0031","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.013_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13153868","article-title":"Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study","volume":"13","author":"Onishi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.898774","article-title":"Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With De Novo Lymph Node-Positive Prostate Cancer","volume":"12","author":"Spohn","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.radonc.2013.08.006","article-title":"Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome","volume":"109","author":"Fonteyne","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.radonc.2019.09.027","article-title":"PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years","volume":"141","author":"Shakespeare","year":"2019","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.013_bib0037","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.brachy.2020.05.007","article-title":"Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer","volume":"19","author":"Fischer-Valuck","year":"2020","journal-title":"Brachytherapy"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.013_bib0038","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034623","article-title":"Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL)","volume":"10","author":"Murthy","year":"2020","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0041","first-page":"1549","article-title":"Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer","volume":"38","author":"Yang","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0042","article-title":"Local Therapy in Metastatic Prostate Cancer: Does the Burden of Disease Matter? Results from a National Population-Based Cancer Registry","volume":"197","author":"Venkatramani","year":"2017","journal-title":"J Urology"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.10.011","article-title":"External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA","volume":"39","author":"Stolzenbach","year":"2021","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0044","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/pcan.2016.63","article-title":"Treatment of M1a\/M1b prostate cancer with or without radical prostatectomy at diagnosis","volume":"20","author":"Moschini","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.013_bib0045","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/pros.23519","article-title":"Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages","volume":"78","author":"Pompe","year":"2018","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.013_bib0046","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0047","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0048","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0049","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","article-title":"Systemic and Tumor-directed Therapy for Oligometastatic Prostate Cancer: The SOLAR Phase 2 Trial in De Novo Oligometastatic Prostate Cancer","volume":"86","author":"Nickols","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0050","first-page":"130","article-title":"PEARLS - A multicentre phase II\/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA-avid pelvic and\/or para-aortic lymph nodes at presentation","volume":"37","author":"Murray","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0053","article-title":"1657TiP The STAMPEDE2 stereotactic ablative body radiotherapy (SABR) trial: A phase III, randomised, open-label trial in patients with newly diagnosed oligometastatic prostate cancer (PC) starting androgen deprivation therapy (ADT)","volume":"35","author":"Hea","year":"2024","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0055","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.013_bib0056","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bju.12342","article-title":"Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis","volume":"114","author":"Passoni","year":"2014","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0057","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","volume":"55","author":"Briganti","year":"2009","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0058","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.eururo.2008.05.023","article-title":"Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy","volume":"54","author":"Schumacher","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0059","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0022-5347(05)64670-8","article-title":"Is a limited lymph node dissection an adequate staging procedure for prostate cancer?","volume":"168","author":"Bader","year":"2002","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2021.04.031","article-title":"Radical prostatectomy for localized prostate cancer: 20-year oncological outcomes from a German high-volume center","volume":"39","author":"Wurnschimmel","year":"2021","journal-title":"Urol Oncol"},{"issue":"6 Pt 1","key":"10.1016\/j.semradonc.2025.04.013_bib0061","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1097\/01.ju.0000143448.04161.cc","article-title":"Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results","volume":"172","author":"Daneshmand","year":"2004","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0062","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.013_bib0063","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.semradonc.2025.04.013_bib0064","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bju.12623","article-title":"A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy \u2013 Adjuvant Versus Early Salvage (RAVES) trial","volume":"113","author":"Pearse","year":"2014","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0065","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1464-410X.2007.06844.x","article-title":"Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council\/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy","volume":"99","author":"Parker","year":"2007","journal-title":"BJU Int"},{"issue":"10260","key":"10.1016\/j.semradonc.2025.04.013_bib0066","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.semradonc.2025.04.013_bib0067","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1200\/JCO.21.02800","article-title":"Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for pN1 Prostate Cancer and the Risk of Death","volume":"40","author":"Tilki","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0068","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of Patient Selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"},{"issue":"35","key":"10.1016\/j.semradonc.2025.04.013_bib0069","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.013_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2024.03.015","article-title":"Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium","volume":"42","author":"Triner","year":"2024","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0071","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.013_bib0072","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1470-2045(21)00242-4","article-title":"Elective nodal radiotherapy in prostate cancer","volume":"22","author":"De Meerleer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0073","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.radonc.2019.05.016","article-title":"Radiotherapy for node-positive prostate cancer: 2019 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group","volume":"140","author":"Lieng","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0074","article-title":"Elective pelvic nodal irradiation in the setting of ultrahypofractionated versus moderately hypofractionated and conventionally fractionated radiotherapy for prostate cancer: Outcomes from 3 prospective clinical trials","volume":"49","author":"Glicksman","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"issue":"10442","key":"10.1016\/j.semradonc.2025.04.013_bib0075","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109544","article-title":"ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer","volume":"183","author":"Schmidt-Hegemann","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.semradonc.2025.04.013_bib0077","doi-asserted-by":"crossref","DOI":"10.1038\/s41391-024-00878-0","article-title":"Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting","author":"Achard","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.013_bib0078","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.eururo.2011.02.024","article-title":"Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis","volume":"59","author":"Briganti","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.013_bib0079","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2009.01.046","article-title":"Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy","volume":"55","author":"Da Pozzo","year":"2009","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.013_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.06.017","article-title":"Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer","volume":"34","author":"Wong","year":"2016","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0081","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/cncr.30373","article-title":"The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer","volume":"123","author":"Jegadeesh","year":"2017","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0082","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies","volume":"73","author":"Touijer","year":"2018","journal-title":"Eur Urol"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.013_bib0083","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2024.42.4_suppl.131","article-title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL)","volume":"42","author":"Posadas","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.04.013_bib0084","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0085","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.euo.2020.01.005","article-title":"Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial","volume":"4","author":"Bitting","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.013_bib0086","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The Impact of (68)Ga-PSMA PET\/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.013_bib0087","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/1754-9485.13655","article-title":"Prognostic impact of prostate-specific membrane antigen positron emission tomography (PSMA PET) staging for clinically node-positive prostate cancer","volume":"68","author":"Leow","year":"2024","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.013_bib0088","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1097\/RLU.0000000000005284","article-title":"Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET\/CT and Conventional Imaging","volume":"49","author":"Onal","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.013_bib0089","doi-asserted-by":"crossref","DOI":"10.2196\/11256","article-title":"Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial","volume":"7","author":"Draulans","year":"2018","journal-title":"JMIR Res Protoc"},{"issue":"18","key":"10.1016\/j.semradonc.2025.04.013_bib0090","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","article-title":"Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease","volume":"35","author":"Spratt","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.013_bib0091","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.013_bib0092","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/clinpract14020039","article-title":"Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX","volume":"14","author":"Bologna","year":"2024","journal-title":"Clin Pract"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:06:10Z","timestamp":1750791970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000414"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.013","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy in Node-Positive Prostate Cancer: Current Evidence and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}